Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Dow
Johnson and Johnson
Merck

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

NUVARING Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Nuvaring, and when can generic versions of Nuvaring launch?

Nuvaring is a drug marketed by Organon Sub Merck and is included in one NDA.

The generic ingredient in NUVARING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.

Drug patent expirations by year for NUVARING
Drug Prices for NUVARING

See drug prices for NUVARING

Drug Sales Revenue Trends for NUVARING

See drug sales revenues for NUVARING

Recent Clinical Trials for NUVARING

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 4
National Institute of Allergy and Infectious Diseases (NIAID)Phase 4
University of WashingtonPhase 4

See all NUVARING clinical trials

Recent Litigation for NUVARING

Identify potential future generic entrants

District Court Litigation
Case NameDate
Merck Sharp & Dohme B v. v. Dr. Reddy's Laboratories, S.A.2015-09-11
Merck Sharp & Dohme B v. v. Warner Chilcott Company LLC2013-12-24

See all NUVARING litigation

Pharmacology for NUVARING
Synonyms for NUVARING
131562-74-8
135988-10-2
18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17alpha)-, mixt. with (17alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol
Ethinyl estradiol and etonogestrel
Ethinylestradiol mixture with etonogestrel
Ethinylestradiol-3-oxodesogestrel mixt.
Etonogestrel and ethinyl estradiol
Etonogestrel-ethynylestradiol mixt.
Etonogestrel/Ethinyl Estradiol Vaginal Ring
LS-187950
SCHEMBL20544194

US Patents and Regulatory Information for NUVARING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Sub Merck NUVARING ethinyl estradiol; etonogestrel RING;VAGINAL 021187-001 Oct 3, 2001 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for NUVARING
Drugname Dosage Strength RLD Date
➤ Subscribe Vaginal Ring 0.015 mg/24 hour and 0.12 mg/24 hour ➤ Subscribe   Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Dow
AstraZeneca
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.